To include your compound in the COVID-19 Resource Center, submit it here.

Sage rebounds on Phase III PPD readout

Sage Therapeutics Inc. (NASDAQ:SAGE) jumped $33.99 (54%) to $96.65 Thursday after reporting that brexanolone (formerly SAGE-547) met the primary endpoint in a pair of Phase III trials to treat postpartum depression. Next year, the company

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE